Limitations of Faecal Calprotectin in Detecting Histological Changes and Persistent Villous Atrophy in Patients With Coeliac Disease on a Gluten‐Free Diet
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70114 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Verónica Segura and 9 co-authors. Institution: Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain. Major MEDLINE topics: Leukocyte L1 Antigen Complex, Celiac Disease, Feces, Diet, Gluten-Free. Cited 1 times so far (Crossref); 14 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Junta de Andalucía (Fundación Pública Andaluza Progreso y Salud, Spain).
Abstract (original language)
Faecal calprotectin is used to assess intestinal inflammation, but its role in monitoring mucosal healing in coeliac disease is unclear. This study followed 48 adults with coeliac disease on a gluten‐free diet over 12 months, evaluating faecal calprotectin levels in correlation with anti‐transglutaminase antibodies, gluten‐free diet adherence by dietary questionnaires and histology. Although significant histological lesions (Marsh II–III) decreased from 24% to 10%, faecal calprotectin levels fluctuated without correlation to anti‐transglutaminase, adherence or histological remission, and did not differentiate between lesion grades. Our findings underscore faecal calprotectin's unreliability in monitoring mucosal healing in adults with coeliac disease, highlighting the urgent need for alternative biomarkers.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain.
- Digestive Disease Clinical Unit and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group, Virgen del Rocío Hospital/CSIC/US, Seville, Spain.
- Clinical Analysis Service, Hospital Universitario INGESA, Ceuta, Spain.
- Centro de Salud Amante Laffón, Seville, Spain.
- Digestive Diseases Clinical Unit, Department of Medicine, Faculty of Medicine, Virgen Macarena Hospital, University of Seville, Seville, Spain.
ORCID profiles: Verónica Segura, Ángela Ruiz-Carnicer, Ángeles Pizarro, Cristóbal Coronel-Rodríguez, Federico Argüelles-Arias, Marta Garzón-Benavides, Carolina Sousa, Isabel Comino
Funding
- Junta de Andalucía (Fundación Pública Andaluza Progreso y Salud, Spain)
Cite
APA
Segura, V., Ruiz-Carnicer, Á., Pizarro, Á., González-Naranjo, C., Díaz, J., Coronel-Rodríguez, C., Argüelles-Arias, F., Garzón-Benavides, M., Sousa, C., & Comino, I. (2025). Limitations of Faecal Calprotectin in Detecting Histological Changes and Persistent Villous Atrophy in Patients With Coeliac Disease on a Gluten‐Free Diet. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70114
Vancouver
Segura V, Ruiz-Carnicer Á, Pizarro Á, González-Naranjo C, Díaz J, Coronel-Rodríguez C, et al. Limitations of Faecal Calprotectin in Detecting Histological Changes and Persistent Villous Atrophy in Patients With Coeliac Disease on a Gluten‐Free Diet. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70114
BibTeX
@article{Segura2025,
author = {Segura, Verónica and Ruiz-Carnicer, Ángela and Pizarro, Ángeles and González-Naranjo, Carmen and Díaz, Jacobo and Coronel-Rodríguez, Cristóbal and Argüelles-Arias, Federico and Garzón-Benavides, Marta and Sousa, Carolina and Comino, Isabel},
title = {Limitations of Faecal Calprotectin in Detecting Histological Changes and Persistent Villous Atrophy in Patients With Coeliac Disease on a Gluten‐Free Diet},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70114}
}
EUVIMED